Literature DB >> 11457533

A Brucella ovis antigenic complex bearing poly-epsilon-caprolactone microparticles confer protection against experimental brucellosis in mice.

M Murillo1, M J Grilló, J Reñé, C M Marín, M Barberán, M M Goñi, J M Blasco, J M Irache, C Gamazo.   

Abstract

A hot saline antigenic extract (HS) from Brucella ovis was encapsulated in poly-epsilon-caprolactone microparticles (PEC), and tested as a vaccine against B. ovis and B. abortus infections in mice. Subcutaneous but not oral administration in BALB/c mice of the HS-PEC induced high amounts of IFN-gamma and IL-2 but low quantities of IL-4 suggesting a combined Th1/Th2 cellular immune response. The vaccine administered either subcutaneously or orally protected mice against B. ovis infection. Such protection was similar to that provided by the reference living attenuated B. melitensis Rev. 1 vaccine. By contrast, only the subcutaneous vaccination with HS-PEC was as effective as Rev. 1 in conferring protection against B. abortus infection. The use of free HS or empty PEC microparticles did not produce any protective effect.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11457533     DOI: 10.1016/s0264-410x(01)00177-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Stability of poly(epsilon-caprolactone) microparticles containing Brucella ovis antigens as a vaccine delivery system against brucellosis.

Authors:  Maite Estevan; Carlos Gamazo; Fernando Martínez-Galan; Juan M Irache
Journal:  AAPS PharmSciTech       Date:  2008-10-16       Impact factor: 3.246

2.  Subcellular fractions of Brucella ovis distinctively induce the production of interleukin-2, interleukin-4, and interferon-gamma in mice.

Authors:  E Salas-Téllez; A Núñez del Arco; V Tenorio; E Díaz-Aparicio; M de la Garza; F Suárez-Güemes
Journal:  Can J Vet Res       Date:  2005-01       Impact factor: 1.310

3.  Optimization of stability, encapsulation, release, and cross-priming of tumor antigen-containing PLGA nanoparticles.

Authors:  Shashi Prasad; Virginia Cody; Jennifer K Saucier-Sawyer; Tarek R Fadel; Richard L Edelson; Martin A Birchall; Douglas J Hanlon
Journal:  Pharm Res       Date:  2012-07-14       Impact factor: 4.200

4.  Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy.

Authors:  Shashi Prasad; Virginia Cody; Jennifer K Saucier-Sawyer; W Mark Saltzman; Clarence T Sasaki; Richard L Edelson; Martin A Birchall; Douglas J Hanlon
Journal:  Nanomedicine       Date:  2010-08-06       Impact factor: 5.307

5.  Encapsulated Brucella ovis Lacking a Putative ATP-Binding Cassette Transporter (ΔabcBA) Protects against Wild Type Brucella ovis in Rams.

Authors:  Ana Patrícia C Silva; Auricélio A Macêdo; Luciana F Costa; Cláudia E Rocha; Luize N N Garcia; Jade R D Farias; Priscilla P R Gomes; Gustavo C Teixeira; Kessler W J Fonseca; Andréa R F Maia; Gabriela G Neves; Everton L Romão; Teane M A Silva; Juliana P S Mol; Renata M Oliveira; Márcio S S Araújo; Ernane F Nascimento; Olindo A Martins-Filho; Humberto M Brandão; Tatiane A Paixão; Renato L Santos
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

6.  Meta-Analysis and Advancement of Brucellosis Vaccinology.

Authors:  Tatiane F Carvalho; João Paulo A Haddad; Tatiane A Paixão; Renato L Santos
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

7.  Evaluation in mice of Brucella ovis attenuated mutants for use as live vaccines against B. ovis infection.

Authors:  Pilar Sancho; Carmen Tejedor; Rebeca S Sidhu-Muñoz; Luis Fernández-Lago; Nieves Vizcaíno
Journal:  Vet Res       Date:  2014-06-04       Impact factor: 3.683

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.